Circulating Cell-Free DNA Can Predict RhD Status in Pregnancy

Share this content:
Circulating Cell-Free DNA Can Predict RhD Status in Pregnancy
Circulating Cell-Free DNA Can Predict RhD Status in Pregnancy

WEDNESDAY, Nov. 16, 2016 (HealthDay News) -- Circulating cell-free DNA can predict fetal RHD status throughout pregnancy, according to a study published in the December issue of Obstetrics and Gynecology.

Kenneth J. Moise Jr., M.D., from the Baylor College of Medicine in Houston, and colleagues conducted a prospective observational study to assess the accuracy of a new assay to determine fetal RHD status using circulating cell-free DNA. They obtained maternal blood samples in each trimester of pregnancy from 520 non-alloimmunized RhD-negative patients. Using the SensiGENE RHD test, plasma samples were analyzed for circulating cell-free DNA. Using cord blood at birth, neonatal serology for RhD typing was undertaken. Results of the DNA analysis were compared with the neonatal serology.

The researchers found that there were inconclusive results secondary to the presence of the RHD pseudogene or an RHD variant in 5.6, 5.7, and 6.1 percent of samples from the first, second, and third trimesters, respectively. The corresponding false-positive rates for RhD were 1.54, 1.53, and 0.82 percent. Only one false-negative diagnosis was observed, which occurred in the first trimester. This error was found to be due to mislabeling of samples from two patients. Across all three trimesters, the overall test results were in agreement (P > 0.99).

"Circulating cell-free DNA can accurately predict the fetal RhD status in all three trimesters of pregnancy," the authors write.

One author disclosed financial ties to Sequenom, which manufactures the SensiGENE RHD test and funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves New Parkinson's Add-On Drug Xadago

FDA Approves New Parkinson's Add-On Drug Xadago

To help prevent 'off' episodes among users of levodopa/carbidopa

Infant Mortality Down in United States From 2005 to 2014

Infant Mortality Down in United States From 2005 ...

Largest decreases seen for infants of Asian or Pacific Islander and non-Hispanic black women

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive alveolar recruitment strategy linked to less severe pulmonary complications after cardiac sx

is free, fast, and customized just for you!

Already a member?

Sign In Now »